$310/0.1 mL | $570/0.1 mL (Biotin) | $1,330/5x0.1 mL | $570/0.1 mL (FITC) | $570/0.1 mL (AF350) | $570/0.1 mL (AF405) | $570/0.1 mL (AF488) | $570/0.1 mL (AF555) | $570/0.1 mL (AF568)
$310/0.1 mL | $570/0.1 mL (Biotin) | $1,330/5x0.1 mL | $570/0.1 mL (FITC) | $570/0.1 mL (AF350) | $570/0.1 mL (AF405) | $570/0.1 mL (AF488) | $570/0.1 mL (AF555) | $570/0.1 mL (AF568)
$310/0.1 mL | $570/0.1 mL (Biotin) | $1,330/5x0.1 mL | $570/0.1 mL (FITC) | $570/0.1 mL (AF350) | $570/0.1 mL (AF405) | $570/0.1 mL (AF488) | $570/0.1 mL (AF555) | $570/0.1 mL (AF568)
$480/0.1 mL (Biotin) | $480/0.1 mL (AF350) | $480/0.1 mL (AF405) | $480/0.1 mL (AF488) | $480/0.1 mL (AF555) | $480/0.1 mL (AF594) | $480/0.1 mL (AF647) | $480/0.1 mL (AF680) | $480/0.1 mL (AF750)
Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were Purified by affinity-chromatography using epitope-specific peptide.
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Dot Blot (DB) (Dot blot analysis of Phospho-RAF1-S43 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antobodies working concentration was 0.5ug per ml.)
Dot Blot (DB) (Dot blot analysis of phospho-BRAF-T439 polyclonal antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5ug per ml. P-Pab: phospho-antibody; P-Peptide: phospho-peptide; NP-Peptide: non-phospho-peptide.)
Testing Data (3T3/A31 cell lysate was probed with R0495-06 (2ug/ml).)
Western Blot (WB) (Western blot analysis of extracts of C6 cell line, using RAF-1 antibody.)
Testing Data (Detection limit for recombinant GST tagged BRAF is approximately 3ng/ml as a capture antibody.)
Testing Data (Detection limit for recombinant GST tagged BRAF is approximately 0.1ng/ml as a capture antibody.)
Testing Data (Detection limit for recombinant GST tagged BRAF is approximately 0.1ng/ml as a capture antibody.)
Immunofluorescence (IF) (Immunofluorescence of monoclonal antibody to BRAF on HeLa cell. [antibody concentration 10 ug/ml])
Immunofluorescence (IF) (Immunofluorescence of monoclonal antibody to BRAF on HeLa cell. [antibody concentration 10 ug/ml])
Dot Blot (DB) (Dot blot analysis of anti-BRAF Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
Western Blot (WB) (Western blot analysis of Phospho-Raf1 (S43) on different lysates using anti-Phospho-Raf1 (S43) antibody at 1/1, 000 dilution. Positive control: Lane 1: NIH/3T3 Lane 2: 293T)
Dot Blot (DB) (Dot blot analysis of Phospho-RAF1-S471 polyclonal antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5ug per ml. P-Pab: phospho-antibody; P-Peptide: phospho-peptide; NP-Peptide: non-phospho-peptide.)
Dot Blot (DB) (Dot blot analysis of Phospho-RAF1-S471 polyclonal antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5ug per ml. P-Pab: phospho-antibody; P-Peptide: phospho-peptide; NP-Peptide: non-phospho-peptide.)
Dot Blot (DB) (Dot blot analysis of anti-BRAF-pS445 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
Western Blot (WB) (Western blot analysis of extracts from 293 cells using Raf1(Ab-338) Antibody and the same antibody preincubated with blocking peptide.)
Immunohistochemistry (IHC) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Raf1(Ab-338) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Western Blot (WB) (Western blot analysis of extracts from HuvEc, using C-RAF (Phospho-Ser301) antibody. The lane on the right is treated with the synthesized peptide.)
Western Blot (WB) (Western blot analysis of extracts from COS7 cells (Lane 2), using C-RAF (Phospho-Ser301) Antibody. The lane on the left is treated with synthesized peptide.)
Western Blot (WB) (Western Blot analysis in MCF7 cell line lysates (35ug/lane) usingMBS625306. ARAF1 (arrow) was detected using the purified Pab.)
Immunohistochemistry (IHC) (Formalin-fixed and paraffin-embedded human cancer tissue reacted withMBS625306, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry. BC = breast carcinoma; HC = hepatocarcinoma.)
Western Blot (WB) (Western blot analysis of extracts from Jurkat cells treated with Paclitaxel using Raf1 (Phospho-Tyr341) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Immunohistochemistry (IHC) (Immunohistochemical analysis of paraffin-embedded human pancreas tissue using Raf1 (Phospho-Tyr341) antibody (left)or the same antibody preincubated with blocking peptide (right).)
Western Blot (WB) (Western Blot analysis in MCF7 cell line lysates (35ug/lane) usingMBS625306. ARAF1 (arrow) was detected using the purified Pab.)
Immunohistochemistry (IHC) (Formalin-fixed and paraffin-embedded human cancer tissue reacted withMBS625306, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry. BC = breast carcinoma; HC = hepatocarcinoma.)
Western Blot (WB) (Western Blot analysis in MCF7 cell line lysates (35ug/lane) usingMBS625306. ARAF1 (arrow) was detected using the purified Pab.)
Immunohistochemistry (IHC) (Formalin-fixed and paraffin-embedded human cancer tissue reacted withMBS625306, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry. BC = breast carcinoma; HC = hepatocarcinoma.)
Western Blot (WB) (Western Blot detection against Immunogen (36.74kD).)
Western Blot (WB) (BRAF monoclonal antibody. Western Blot analysis of BRAF expression in human pancreas.)
Testing Data (Detection limit for recombinant GST tagged BRAF is ~0.03ng/ml as a capture antibody.)
Testing Data (Proximity Ligation Analysis (PLA) of protein-protein interactions between MAPK3 and BRAF. HeLa cells were stained with MAPK3 rabbit purified polyclonal 1:1200 and BRAF mouse monoclonal antibody 1:50. Signals were detected by 30 Detection Kit 613 (red), and nuclei were counterstained with DAPI (blue). Each red dot represents the detection of protein-protein interaction complex.)
Western Blot (WB) (Western Blot detection against Immunogen (36.74kD).)
Western Blot (WB) (BRAF monoclonal antibody. Western Blot analysis of BRAF expression in human pancreas.)
Testing Data (Detection limit for recombinant GST tagged BRAF is ~0.03ng/ml as a capture antibody.)
Testing Data (Proximity Ligation Analysis (PLA) of protein-protein interactions between MAPK3 and BRAF. HeLa cells were stained with MAPK3 rabbit purified polyclonal 1:1200 and BRAF mouse monoclonal antibody 1:50. Signals were detected by 30 Detection Kit 613 (red), and nuclei were counterstained with DAPI (blue). Each red dot represents the detection of protein-protein interaction complex.)
Western Blot (WB) (Western blot analysis of anti-RAF1 Pab in Jurkat cell lysate. RAF1 (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.)
Immunohistochemistry (IHC) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
Immunofluorescence (IF) (Confocal immunofluorescent analysis of RAF1 Antibody (N-term) with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).)
Flow Cytometry (FC/FACS) (RAF1 Antibody (N-term) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.)
Immunofluorescence (IF) (Immunofluorescence analysis of HeLa cells using ARAF antibody.)
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.